Researchers escaped OpenAI's Codex sandbox two ways, one running commands on a developer's machine from its most locked-down mode. OpenAI has patched both.
In January, Meta CEO Mark Zuckerberg and his top lieutenants gathered for their annual leadership retreat at his Hawaii compound. There they hatched a radical plan to reimagine work at the ...
Like many great partnerships, it started with an argument. For months, Amjad Masad had been locked in a playful battle of wits with Haya Odeh, a young graphic designer at Boss Consulting SA, a web ...
Lucas Kloberdanz-Dyck is a writer for Collider. He grew up creating lists, stories, and worlds, which led to his love of anime and video games. He attended Sheridan College where he earned an Honours ...
The last time I spoke about Replimune Group, Inc. (REPL), it was with a Seeking Alpha article entitled "Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating." With respect to this ...
A massive malvertising campaign is using fake Solana, Luno, and TradingView webpages with malicious JavaScript that instructs browsers to assemble malware directly in memory. The operation has been ...
Since the large language model (LLM) explosion started, companies have been trying to solve the problem of overflowing inboxes by using AI to categorize emails and draft replies that sound like you.
JavaScript Statistics: JavaScript is a type of scripting language for creating dynamic web page content. It designs elements to improve site visitors’ interlinkage with the web pages, such as animated ...
The FDA indicated that it will treat the filing as an urgent matter and prioritize the review process. The FDA had twice rejected the application earlier, leading to Replimune’s CEO Sushil Patel ...
This project is a proof-of-concept that runs a JavaScript engine inside a web browser by compiling it to WebAssembly. The engine is Goja — a pure-Go implementation of ECMAScript 5.1 — and the ...
Replimune Group Inc. stocks have been trading down by -67.12 percent amid heightened concern over trial setbacks and regulatory uncertainty. Live Update At 10:02:59 EDT: On Monday, April 13, 2026 ...
Jefferies said it sees a ‘tough road ahead’ for Replimune after the FDA’s rejection of RP-1. JPMorgan called the rejection “disappointing,” adding that overall RP1 data supported FDA approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results